



August 31, 2023
JCR Pharmaceuticals Co., Ltd.

Translation

Notice regarding Sponsorship for Relay for Life Japan

August 31, 2023-- Relay for Life conducts charity activities to support cancer patients and their families, aiming for the entire community to face up to and overcome cancer. JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") endorses the objectives of these activities and will sponsor Relay for Life Japan and Relay for Life Japan in Ashiya again this year.

In 1985, a physician ran around an athletic track for 24 hours and collected donations for the American Cancer Society, Inc. The run was to share and support the idea that cancer patients face up to their cancer 24 hours a day. The event, which hopes to generate courage and hope by walking and communicating together, is now held in about 4,500 places in 32 countries around the world.



In Japan, Relay for Life activities are also spreading, and in FY2022 were held in 47 locations throughout the country. The city of Ashiya, Hyogo Prefecture, has been holding this event officially since 2007, and will run it for the 17th time under the main theme of: "I started to walk in this place. I will meet you again in this place."

JCR, which aims for the realization of a society where no one will be left behind, has sponsored this activity since 2017, marking its seventh occasion this year, and contributes to patients and their families through activities.

Please refer to the official websites below for more information about these activities.

- Relay for Life Japan (only in Japanese): <https://relayforlife.jp/>
- Relay for Life Japan in Ashiya (only in Japanese): <https://relayforlife.jp/ashiya/>

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation

therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###